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The results from three studies determining the efﬁcacy of a canine multivalent vaccine in the presence of
maternal antibodies are reported. Each study used 15 six week old dogs; ﬁve dogs were sero-negative;
the remaining 10 had maternally derived antibodies to CDV, CAV and CPV. The ﬁve MDA-negative dogs
and ﬁve of the MDA-positive dogs were vaccinated twice with the vaccine while the remaining 5 MDA-
positive dogs were administered sterile water. According to EU guidelines for MDA studies dogs were
challenged when maternally-derived antibodies in non-vaccinated dogs had greatly diminished or disap-
peared (3–5 weeks after second vaccination); clinical observations and rectal temperatures were
recorded, and sera and faecal samples (CPV study only) were collected throughout the study.
After challenge, non-vaccinated dogs showed clinical signs of infection while none of the vaccinated
dogs did. MDA-negative vaccinated dogs sero-converted with increases in titre observed after each vac-
cination, and further increases observed after challenge. MDA-positive vaccinated dogs showed declining
antibody titres following the ﬁrst vaccination, but increases after the second vaccination and further
increases after challenge. In all vaccinated dogs the immune responses generated were protective, irre-
spective of the presence of maternal antibodies, as demonstrated by heterologous viral challenge.
In conclusion, two doses of the DHPPi/L4R vaccine administered to dogs from six weeks of age in the
presence of maternal antibodies aided in the protection against virulent challenge with CDV, CAV-1 or
CPV.
 2014 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
For over a decade canine vaccines have been categorised into
core, non-core and non-recommended groups [7], with canine dis-
temper, parvovirus and adenovirus considered core vaccine com-
ponents. These categories have been further developed and
currently form the basis of the World Small Animal Veterinary
Association (WSAVA) Guidelines for the Vaccination of Dogs and
Cats [16].
Active immunisation of dogs is essential at reducing the risk of
contracting infectious diseases and in particular viral infections [3].
As vaccine administration has become more routine and wide-spread, the incidence of most commonly observed diseases has
been reduced, although there are occasional outbreaks in vacci-
nated animals [10]. Vaccine technology has also evolved in line
with new disease agents to provide improved performance or
broader efﬁcacy [1].
Maternally derived immunity is considered the primary cause
of vaccine failure in young dogs [6,8,12]. To overcome interference
by maternally derived antibodies (MDA), and ensure protection
when maternal antibody levels wane, it is recommended to vacci-
nate puppies repeatedly between 6 and 16 weeks of age. However,
this is logistically demanding and most products now have a single
or double vaccination regimen depending on the age of dog and
whether MDA are expected to be present. Although MDA was
thought to have more of an impact on live vaccine components,
recent studies have demonstrated that maternal antibodies can
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following administration of vectored [11] or adjuvanted killed
antigen vaccines [14,15]. What these studies, and others in dogs
[2] have shown is that the level of maternal antibodies has a signif-
icant inﬂuence on the ability of a vaccine to generate a passive
immune response, with decreasing maternal antibody levels per-
mitting more response from the vaccine.
In this paper we describe the efﬁcacy of a new multivalent vac-
cine (DHPPi/L4R), containing the core viral components, when
administered to dogs from six weeks of age in the presence of
maternally derived antibodies. Dogs were challenged following
vaccination and the impact of vaccination on clinical variables
and serology was examined by comparing MDA-positive and
MDA-negative vaccinated dogs to MDA-positive non-vaccinated
dogs in each study.
Materials and methods
This study reports the results of three European Pharmacopeia
monograph compliant trials investigating the efﬁcacy of canine
distemper virus (CDV; monograph 01/2008:0448), canine adenovi-
rus type 2 (CAV-2; monograph 01/2008:1951) and canine parvovi-
rus (CPV; monograph 01/2008:0964) in a new multivalent vaccine
for dogs. The studies were conducted in accordance with the Act on
Animal Health and Animal Welfare of The Czech Republic, and had
been approved by Bioveta a.s. and Zoetis ethical review commit-
tees. Day 0 was when dogs received the ﬁrst administration of vac-
cine or sterile water.
Animals
In each study ﬁfteen 6-week old Beagle dogs were enrolled. Five
dogs were sero-negative (MDA) with the remaining ten dogs,
randomly allocated to two groups, being sero-positive to CDV,
CPV, CAV-1 and CAV-2 (MDA+), at titres comparable to those
observed in the ﬁeld; MDA titres prior to ﬁrst vaccination are
shown in Table 1. The MDA-negative pups were derived from SPF
dams, while the MDA-positive pups were derived from conven-
tional health status dams which had been vaccinated with the test
vaccine described below. All dogs were of good general health and
free from infection with the viral agents contained within the vac-
cine. Dogs from the MDA group and one MDA+ group were vac-
cinated with DHPPi/L4R. Dogs from the second MDA+ group served
as controls and were administered sterile water. After the second
test material administration, all vaccinated dogs (MDA andTable 1
Maternal derived antibody titres prior to ﬁrst vaccination. All results shown are virus neut
than 50% of the characteristic cytopathic effect was attenuated. Different groups of dogs w
Animal Treatment Study one
CAV-1
1 MDA-negative; vaccinated <2
2 <2
3 <2
4 <2
5 <2
1 MDA-positive; vaccinated 64
2 64
3 64
4 P256
5 64
1 MDA-positive; controls 128
2 128
3 64
4 128
5 128MDA+) and two non-vaccinated dogs (MDA+), with greatly dimin-
ished or no MDAs and selected at random by a company biometri-
cian, were challenged with the relevant challenge virus.Vaccine
An experimental vaccine batch was produced which contained
modiﬁed live CDV, canine parainﬂuenza virus (CPiV), CAV-2,
CPV-2b (DHPPi), inactivated Leptospira interrogans serovars
Canicola, Icterohaemorrhagiae and Bratislava, Leptospira kirschneri
serovar Grippotyphosa, and rabies virus (L4R). The DHPPi compo-
nent was freeze-dried while the L4R component was a liquid con-
taining adjuvant (aluminium hydroxide). The control product was
sterile water. Administration (1 ml) was by the subcutaneous route
behind the left shoulder blade on day 0 and behind the right shoul-
der blade on day 21, using standard aseptic technique.Challenge
CDV isolate Snyder Hill was obtained from the American Type
Culture Collection (ATCC); the CAV-1 isolate Mirandola was
obtained from the Animal and Plant Health Inspection Services,
Centre for Veterinary Biologics (APHIS, CVB); and the CPV-2b iso-
late 212/98 was obtained from the University of Bari, Italy. For
the CDV (101 dilution of an unknown titre virus stock) and
CAV-1 (106.3 TCID50/mL) studies 1 mL of challenge material was
administered by the intravenous route on day 42; for CPV (106.6
TCID50/mL) a 2 mL dose was administered with 1 mL orally and
1 mL intranasally (0.5 mL per nostril) on day 56. The day of CPV
challenge was postponed by 2 weeks from day 42 to day 56,
because the MDA+, non-vaccinated control dogs still had detect-
able maternal antibodies on day 28 and day 35.Observations and samples
Rectal temperatures (C) of all animals were recorded daily for a
period of seven days after each vaccination, and from prior to chal-
lenge strain administration until the end of the study. Clinical
observations were performed daily from day-2 until the end of
the study. Additional general health observations were performed
at least once daily at times distinct from clinical observations. Any
dogs which exhibited signs of disease, such that in the opinion of
the examining veterinarian their welfare was seriously affected,
were euthanased as appropriate to avoid unnecessary suffering.ralisation titres where the end point was assessed as the serum dilution where more
ere used in each of the three studies.
Study two Study three
CAV-2 CPV-2 CPV-2b CDV
<2 <5 <5 <2
<2 <5 <5 <2
<2 <5 <5 <2
<2 <5 <5 <2
<2 <5 <5 <2
32 320 5120 4
64 80 640 8
128 320 640 4
128 320 2560 2
64 640 2560 2
64 640 1280 8
128 160 1280 16
64 320 2560 8
128 160 5120 4
128 80 1280 8
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material (vaccine or control) administration on day 0, and then
weekly until challenge with a ﬁnal sample the end of the study.
For the CPV study further blood samples for white blood cell
(WBC) counts were collected before challenge administration on
day 52, 54 and 56, and then 3, 5, 7, 10, 12 and 14 days post-
challenge.
To determine virus shedding in the CPV study, faecal swabs
were collected into sterile tubes on day 56, before challenge
administration, and then 3, 5, 7, 10, 12 and 14 days post-challenge.
Laboratory analysis
Sera samples collected were examined for the presence of anti-
bodies to CDV, CPV-2, CPV-2b, CAV-1 and CAV-2 by serum-neutral-
isation test. Brieﬂy, duplicate twofold dilutions were made in
cultivation medium and approximately 100 TCID50 of the respec-
tive virus (vaccine strains) was added followed by incubation at
37 C for 1 h in 5% CO2. Following incubation susceptible cells
(VERO, MDCK or CRFK) were added and incubated at 37 C for 3–
7 days in 5% CO2. The end point was assessed as the serum dilution
where more than 50% of the characteristic cytopathic effect was
attenuated. For the CPV study the end point was determined fol-
lowing 5–7 days cultivation using a haemagglutination with por-
cine red blood cells. For the CPV study, whole blood samples
were analysed for leucocyte counts by staining cells with T}urk’s
solution and counting them in a standard counting chamber. Faecal
samples were examined for virus presence and titre by haemagglu-
tination assay, as described previously [4].
Statistical analysis
Body temperatures were classiﬁed into hypothermic (<37.0 C),
normal (37.0–39.5 C) and hyperthermic (>39.5 C). Descriptive
statistics for antibody titres against relevant antigens including
the geometric mean, minimum and maximum were calculated
for each group of vaccinates and controls at each time point. For
each animal in the CPV study the arithmetic mean of WBC counts
taken up to 4 days pre-challenge was calculated to obtain the base-
line value and post-challengeWBC counts were compared with the
baseline value thereby calculating the percentage reduction. Leu-
copoenia was deﬁned as a decrease of WBC greater than 50% of
the baseline value. The geometric mean of the maximum titres
excreted in faeces of control animals were calculated and com-
pared to the maximum titre excreted in faeces of each vaccinated
animal.Results
Canine distemper
After challenge rectal temperatures in non-vaccinated animals
became elevated, up to 40 C. Non-vaccinated dogs also demon-
strated clinical signs due to distemper virus, including vomiting,
diarrhoea, ocular discharge and apathy; both dogs were euthan-
ased ten or eleven days after challenge. None of the vaccinated ani-
mals, in either the MDA or the MDA+ groups showed any
abnormal clinical signs following challenge.
Serological examinations conﬁrmed that MDA animals did not
have antibodies to CDV before the ﬁrst vaccination (Fig. 1). On day
0, when animals were six weeks of age, titres had declined in
MDA+ vaccinated animals (geometric mean 3.5) and in MDA+
non-vaccinated animals (geometric mean 8.0). The titres of
MDA + non-vaccinated animals continued to decrease until seven
days after the second test material administration when, at10 weeks of age, all control animals were sero-negative. MDA+
non-vaccinated animals were not examined for antibody levels
after challenge, because they were both euthanased prior to the
end of the study.
In MDA+ vaccinated animals, antibody titres decreased until
21 days after the ﬁrst vaccination (geometric mean 1.1). Titres
increased 7 days after the second vaccination in one animal (geo-
metric mean 1.3) and 7 days later in the remaining four animals
(geometric mean 3.5). Titres of all animals were boosted by the
challenge (geometric mean 4.6). In MDA vaccinated animals,
the ﬁrst measurable increases in virus-neutralising antibodies
were detected in three animals 14 days after the ﬁrst vaccination
(geometric mean 3.5). All ﬁve vaccinated animals had sero-con-
verted 21 days (geometric mean 24.3) after the ﬁrst vaccination,
with peak titres 7 (geometric mean 42.2) and 14 days (geometric
mean 42.2) after the second vaccination. After challenge, anamnes-
tic responses in antibody titres were observed in all MDA vacci-
nated animals.
Canine adenovirus type 1 and 2
After challenge, dogs in the MDA vaccinated group showed
normal rectal temperature, while two of ﬁve MDA+ vaccinated
dogs and both of the MDA+ non-vaccinated animals showed
increases with a maximum of 40.3 C observed. Abnormal clinical
signs due to canine hepatitis were observed in one control dog
with diarrhoea, anorexia and abdominal tenderness starting ﬁve
days post challenge. Conjunctivitis and subsequently bilateral cor-
neal opacity (blue eye) were observed from eight days post chal-
lenge. The second control dog showed no abnormal clinical signs,
but died suddenly ﬁve days after challenge. Vaccinated dogs
showed no abnormal clinical signs after challenge.
Serological examinations (Fig. 2) conﬁrmed that MDA vacci-
nated animals did not have antibodies to CAV-1 before the ﬁrst
vaccination. On day 0, when animals were six weeks of age, titres
had declined in MDA+ vaccinated animals (geometric mean 84)
and in MDA+ non-vaccinated animals (geometric mean 111). Anti-
body titres of MDA+ non-vaccinated animals continued to decrease
until challenge (12 weeks of age) when one animal had low titres
and the second dog was sero-negative. Following challenge, the
one surviving dog with low MDA titres before challenge showed
a substantial increase. In MDA+ vaccinated animals, antibody titres
decreased until 14 days (geometric mean 4.0) after the second vac-
cination. Titres then showed an increase 21 days after the second
vaccination (geometric mean 8.0) before titres were boosted by
the challenge. In MDA vaccinated animals, ﬁrst measurable
increases in virus-neutralising antibodies were detected in all but
one animal against CAV-1 seven days (geometric mean 2.6) after
the ﬁrst vaccination; all ﬁve MDA vaccinated animals had sero-
converted by 7 days later (geometric mean 7.0). Antibody titres
peaked 14 days (geometric mean 128.0) after the second vaccina-
tion and then declined until challenge (geometric mean 111.4).
After challenge, anamnestic responses in antibody titres were
observed in all MDA vaccinated animals.
The development of antibody titres to CAV-2 (Fig. 3) mirrored
that of antibodies to CAV-1 except in two points. Both MDA+
non-vaccinated animals were sero-negative (<2) on the day of
challenge on day 42. In MDA+ vaccinated animals, antibody titres
to CAV-2 decreased until seven days after the second vaccination
and then started to rise from 14 days after the second vaccination.
Canine parvovirus
Following challenge with CPV-2b normal rectal temperatures
were observed in dogs from both vaccinated groups. However,
one MDA+ non-vaccinated dog showed hyperthermia between 9
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Fig. 1. Geometric mean CDV antibody titres at each sampling time point by treatment group.  = MDA vaccinated; j = MDA+ vaccinated; N = MDA+ non-vaccinated. Dogs
were vaccinated on days 0 and 21, and challenged on day 42. Error bars are SEM.
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Fig. 2. Geometric mean CAV-1 antibody titres at each sampling time point by treatment group.  = MDA vaccinated;j = MDA+ vaccinated; N = MDA+ non-vaccinated. Dogs
were vaccinated on days 0 and 21, and challenged on day 42. Error bars are SEM.
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thermia 12 days post challenge. Abnormal clinical signs due to
canine parvovirus infection were observed eight days post chal-
lenge with anorexia and apathy, followed 1–3 days later with vom-
iting and diarrhoea in both dogs. The vaccinated dogs from both
MDA and MDA+ groups showed no abnormal clinical signs.
The proﬁle of serological responses against CPV-2 was the same
as for CPV-2b (Fig. 4) with titres generally lower (data not shown).
Serological examinations conﬁrmed that MDA vaccinated ani-
mals did not have antibodies to CPV before the ﬁrst vaccination.
On day 0, when animals were six weeks of age, titres had declined
in MDA+ vaccinated animals (CPV-2 geometric mean 279; CPV-2b
geometric mean 1689) and in MDA+ non-vaccinated animals, (CPV
-2 geometric mean 211; CPV-2b geometric mean 1940). Antibody
titres of MDA+ non-vaccinated animals continued to decrease until
all control animals were sero-negative at 12 weeks of age against
CPV-2 and 13 weeks of age against CPV-2b. Following challenge,
both control animals survived and showed an increase in antibodytitres against CPV-2 (905) and CPV-2b (3620). In MDA+ vaccinated
animals, antibody titres decreased in two animals at 7 days (geo-
metric mean 80) and in three animals at 14 days (geometric mean
69.6) after the second vaccination. Titres then increased until chal-
lenge (CPV-2 geometric mean 640; CPV-2b geometric mean 2941).
After challenge, anamnestic responses in antibody titres were
observed in at least four of ﬁve MDA+ vaccinated animals. In
MDA vaccinated animals, that were negative at the start of the
study, all ﬁve animals had sero-converted seven days after the ﬁrst
vaccination (geometric mean 139.3). Geometric mean titres
against CPV-2b stabilised 21 days after second vaccination until
challenge (CPV-2 geometric mean 1470; CPV-2b geometric mean
5881). After challenge, anamnestic responses in antibody titres
were observed in at least two of ﬁve MDA vaccinated animals.
Examination of white blood cell counts showed that none of the
vaccinated dogs showed a decline in counts below 50% of baseline
pre-challenge values, this being the study deﬁnition of leucopoe-
nia. However, both of the MDA+ non-vaccinated dogs did show a
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Fig. 3. Geometric mean CAV-2 antibody titres at each sampling time point by treatment group.  = MDA vaccinated;j = MDA+ vaccinated; N = MDA+ non-vaccinated. Dogs
were vaccinated on days 0 and 21, and challenged on day 42. Error bars are SEM.
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Fig. 4. Geometric mean CPV-2b antibody titres at each sampling time point by treatment group.  = MDA vaccinated; j = MDA+ vaccinated; N = MDA+ non-vaccinated.
Dogs were vaccinated on days 0 and 21, and challenged on day 56. Error bars are SEM.
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poenic (data not shown). Examination of the faecal samples by
haemagglutination assay (Table 2) indicated small amounts of
excreted CPV ranging from 4 to 16 HAU were detected in two of
ﬁve vaccinated MDA-negative animals on one or two days between
three to ﬁve days after challenge. In three of ﬁve vaccinated MDA-
positive animals small amounts of CPV ranging from 8 to 32 HAU
were detected for one or two days from three to seven days after
challenge. No virus excretion was observed in the remaining vacci-
nated animals and in any of the vaccinated animals from ten days
after challenge. Both control animals excreted CPV from three to
fourteen days after challenge.Discussion
In this paper we evaluated the efﬁcacy of a new canine
multivalent vaccine in the presence of maternally derived antibod-
ies, demonstrating that administration of the two dose vaccinationregimen to dogs at minimum age aids in their protection following
virulent challenge with CDV, CAV-1 and CPV.
From six weeks of age, a rapid decline in antibody titres was
noted in the MDA-positive, non-vaccinated dogs, and the majority
of puppies were sero-negative at the point of challenge when they
were 12 (CDV and CAV-1) or 14 (CPV) weeks of age, that is 3 and
5 weeks after the second vaccination. The half life of antibodies
to canine distemper and canine infectious hepatitis has been dem-
onstrated to be 8.4 days [5], with maternal antibodies to distemper
in puppies declining to levels deemed insigniﬁcant by 10–
12 weeks of age [6]. Maternal antibodies against CPV tend to per-
sist for longer and can in some cases still interfere with vaccination
between 10 and 14 weeks of age [9,13]. The proﬁle of maternal
antibody decline in the non-vaccinated MDA-positive dogs we
observed correlates well with previous work and is therefore likely
to be reﬂective of a ﬁeld situation.
All of the MDA-negative dogs increased antibody titres by three
weeks following the ﬁrst vaccination. Further increases were
observed following the second vaccination, when titres were
Table 2
Examination of faeces samples – haemagglutination test for CPV (HAU/ml).
Treatment Day 56 Day 59 Day 61 Day 63 Day 66 Day 68 Day 70
MDA vaccinated <2 <2 <2 <2 <2 <2 <2
<2 <2 <2 <2 <2 <2 <2
<2 16 <2 <2 <2 <2 <2
<2 <2 <2 <2 <2 <2 <2
<2 4 4 <2 <2 <2 <2
GMT <2 2 <2 <2 <2 <2 <2
MDA+ vaccinated <2 <2 8 8 <2 <2 <2
<2 <2 <2 <2 <2 <2 <2
<2 4 32 <2 <2 <2 <2
<2 <2 <2 <2 <2 <2 <2
<2 <2 <2 8 <2 <2 <2
GMT <2 <2 3 2 <2 <2 <2
Controls <2 32 256 1024 P4096 P4096 256
<2 32 512 2048 1024 P4096 P4096
GMT <2 32 362 1448 2048 4096 1024
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vaccinated dogs. Further increases in antibody titres were observed
again after challenge indicating successful experimental infection.
The vaccinated MDA-positive dogs showed limited responses to
the ﬁrst vaccination but distinct responses to the second vaccina-
tion; these responses were comparable to those seen after the ﬁrst
vaccination in MDA-negative vaccinated dogs. After challenge, all
MDA-positive vaccinated puppies showed further elevated
responses indicating successful challenge infection and immuno-
logical memory response, and therefore the ability of the dogs’
immune system to respond to vaccination in the presence of
maternal antibodies. Despite the lower magnitude of antibody
responses in the MDA-positive, vaccinated dogs compared to the
MDA-negative, vaccinated group the former were successfully pro-
tected against virulent challenge.
The negative impact of maternal antibodies on vaccination is
well known [6] and it is why vaccines are recommended to be
administered on a number of occasions to neonatal dogs. Certainly
for canine parvovirus, any haemagglutination inhibition (HI) titres
greater than 1:20 have been demonstrated to result in dogs failing
to respond to vaccination [13]. As the antibody titres to CPV in the
vaccinated MDA-positive dogs in our investigation declined stea-
dily following the ﬁrst vaccination, it could be assumed that the
initial vaccination was suppressed by maternal antibodies and that
only once MDA serum-neutralisation titres had decreased sufﬁ-
ciently to titres between 1:20 and 1:40 was the second vaccination
able to induce a protective immune response in the neonatal dogs.
Similar scenarios are also probable with the other antigens
examined. In our investigation antibody titres to CDV in the vacci-
nated MDA-positive dogs were at or below the limit of quantiﬁca-
tion (<1:2) prior to second vaccination having shown a rapid
decline over the preceding weeks. In the three weeks after second
vaccination titres increased to similar levels as found two to three
weeks after the ﬁrst vaccination in MDA-negative dogs. In the CAV-
1 study, MDA-positive dogs showed antibody titres between 1:8
and 1:16 against CAV-1 and 1:4 to 1:32 against CAV-2 prior to sec-
ond vaccination. These titres were sufﬁciently low to allow the sec-
ond vaccination to induce protective responses. The presence of
maternal antibody clearly limits the initial impact of vaccination
on young animals, but subsequent boosting with a second vaccina-
tion even in the presence of some residual maternal antibodies
increases the responses to all the vaccine antigens examined here;
CPV, CAV-1, CAV-2 and CDV.Conclusions
In conclusion, we have demonstrated that administration of a
minimum titre, multivalent vaccine to dogs of six weeks of age isefﬁcacious in the presence of maternal antibodies; preventing
mortality and reducing clinical signs of CAV-1 and inducing protec-
tive serological responses to CAV-2; preventing mortality and clin-
ical signs caused by CDV and preventing clinical signs, leucopoenia
and viral excretion caused by CPV.Conﬂict of interest
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